Pfizer nabs European nod for Bosulif; Eisai looks to Mexico for Belviq approval

 @FiercePharma: Lilly works up $180M addition to Indy insulin manufacturing + $80M in other projects. PR hints at city tax incentives: Release | Follow @FiercePharma

 @EricPFierce: Recalls by Hospira encourage other players to jump into sterile injectable drug manufacturing. More | Follow @EricPFierce

> Pfizer ($PFE) won conditional E.U. approval for its new leukemia drug Bosulif, approved by FDA in September. Report

> Eisai submitted an application for Mexican approval for its weight-loss drug Belviq, developed by Arena Pharmaceuticals. More

> The U.S. Chamber of Commerce said it was disappointed in India's Supreme Court ruling against Novartis ($NVS) in a much-watched patent case, adding that investment in R&D could suffer. Story

> Russia's Sistema conglomerate said its stake in Binnopharm dropped to 74% as the unit merged with Alium; Zenitko Finance Management now holds the remaining 26%. Item

> The FDA loosened restrictions on over-the-counter nicotine products, including patches and gum, to allow use for longer than 12 weeks. Report

> AmerisourceBergen plans to sell its packaging business for $308 million. News

Medical Device News

 @FierceMedDev: Seventh Sense revs up crucial trial for microneedle blood collector. More | Follow @FierceMedDev

 @MarkHFierce: The NYT has come out against not just a device tax repeal, but industry lobbying efforts to make their case. Story | Follow @MarkHFierce

 @DamianFierce: AbioMed is studying a next-gen Impella pump targeting FDA approval. Article |& Follow @DamianFierce

> Apollo Endosurgery wins first EU approval. Article

> Life Tech looks to expand cancer, DNA testing presence. Story

> Singapore crew tests Dx for new intestinal lymphoma. More

Biotech News

 @FierceBiotech: Karolinska portfolio biotech Axelar says PhII lung cancer drug on promising track. More | Follow @FierceBiotech

 @JohnCFierce: Clavis' Olav Hellebo says co. could be sold or shut down, but it's all down to liquidation value now. More | Follow @JohnCFierce

 @RyanMFierce: Immunomedics won an $18M settlement from BoA, now it could use an R&D win with those cancer programs. WSJ Article | Follow @RyanMFierce

> Obama seeks revolutionary brain discoveries on a budget. Story

> Analysis: No quick fix in sight for AstraZeneca's PhIII woes. More

> PolyMedix defaults and hands over a PhII antibiotic to bankruptcy court. News

Biotech Research News

 @EmilyMFierce: Waiting for details today on Obama's $100M brain mapping project. Background here: Story | Follow @EmilyMFierce

> More evidence found for new anti-cancer agent. More

> Diabetes drug slows aging process in worms. Report

> Researchers launch consortium to study neurodegenerative diseases. Item

> Dutch researchers detect early Parkinson's pathology. Article

> New drug could combat resistant malaria strains. More

Pharma Manufacturing News

> Manufacturing issues still dog A.P. Pharma. Story

> Japan's Asada Milling gets warning letter. More

> Lilly doubles down on insulin plant, expands API capacity. Article

> Sanofi adding manufacturing capacity in China, Vietnam. Story

And Finally ... Choosing the right playlist helps exercisers stick to their fitness routines. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.